| scholarly article | Q13442814 |
| P356 | DOI | 10.1124/JPET.109.156554 |
| P8608 | Fatcat ID | release_uxrg6qjrlnd2nmwtukj42ncvu4 |
| P698 | PubMed publication ID | 19684251 |
| P2093 | author name string | Hua Yang | |
| Isao Tanaka | |||
| Satoshi Yamamoto | |||
| Masanori Fujita | |||
| Masaki Goto | |||
| Yoshiharu Mizui | |||
| Donna Young | |||
| Fabian Gusovsky | |||
| Kenzo Muramoto | |||
| Hiroshi Shirota | |||
| Jesse Chow | |||
| Yuan J Wang | |||
| Ken-ichi Chiba | |||
| Hiroshi Obaishi | |||
| Kenji Tai | |||
| P2860 | cites work | Resorcylic acid lactones: naturally occurring potent and selective inhibitors of MEK | Q73495196 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 485-495 | |
| P577 | publication date | 2009-08-14 | |
| P1433 | published in | Journal of Pharmacology and Experimental Therapeutics | Q1500272 |
| P1476 | title | E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8, 9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione], a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (M | |
| P478 | volume | 331 |
| Q90630841 | (5Z)-7-Oxozeaenol: A novel and potent resorcylic acid lactone kinase inhibitor with a cis-enone Michael acceptor |
| Q28083145 | A RING to rule them all? Insights into the Map3k1 PHD motif provide a new mechanistic understanding into the diverse roles of Map3k1 |
| Q52684503 | Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. |
| Q64972312 | Allenamide as a bioisostere of acrylamide in the design and synthesis of targeted covalent inhibitors. |
| Q51656630 | An efficient synthesis of an exo-enone analogue of LL-Z1640-2 and evaluation of its protein kinase inhibitory activities |
| Q50043573 | Brain distribution of a novel MEK inhibitor E6201: implications in the treatment of melanoma brain metastases |
| Q89860520 | Current Advances in the Treatment of BRAF-Mutant Melanoma |
| Q27027983 | Developing Irreversible Inhibitors of the Protein Kinase Cysteinome |
| Q38959129 | Discontinued dermatological drugs in 2014. |
| Q54494858 | Docking Simulation Study and Kinase Selectivity of f152A1 and Its Analogs |
| Q36584442 | Effects of (5Z)-7-oxozeaenol on MDA-MB-231 breast cancer cells |
| Q36584470 | Effects of (5Z)-7-oxozeaenol on the oxidative pathway of cancer cells |
| Q38166017 | Emerging topical treatments for psoriasis |
| Q38012518 | Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks |
| Q39510527 | Kinase inhibition by deoxy analogues of the resorcylic lactone L-783277. |
| Q36328021 | MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms |
| Q54688335 | Molecular editing of kinase-targeting resorcylic acid lactones (RAL): Fluoroenone RAL. |
| Q90110385 | Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas |
| Q37974484 | Natural products as kinase inhibitors |
| Q37828536 | Novel mitogen-activated protein kinase kinase inhibitors |
| Q39113154 | Rational Design of Resorcylic Acid Lactone Analogues as Covalent MNK1/2 Kinase Inhibitors by Tuning the Reactivity of an Enamide Michael Acceptor |
| Q88985818 | Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study |
| Q36560775 | Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status |
| Q38747573 | Signaling pathways as therapeutic targets in biliary tract cancer. |
| Q36693252 | The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations |
Search more.